Click image to enlarge
The obvious marginal trend change in Total Prescriptions 2004 to 2006 correlates with: -
1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004 – which found the drug class lacking in safety and efficacy, not notably better than placebo.
2 The "House of Commons, Health Committee’s examination into The Influence of the Pharmaceutical Industry" - initiated June 2004 - report published April 5th 2005.
3 “NICE Clinical Guidelines 23: Depression” published December 2004, issued new guidelines for treatment of depression with the introduction of the “Watchful waiting”; 188.8.131.52 a 2 week waiting period for patients with mild depression who did not want an intervention; and in 184.108.40.206 the GP to contact if the 2 week follow-up appointment not kept; and the restricting treatment initiation and management of Venlafaxine; 220.127.116.11 and in 18.104.22.168 to specialist mental health medical practitioners.
The marginal trend change in Total Prescriptions 2004, caused the anomaly of a Total Prescription Increase of only 402.6 Thousand; the lowest annual SSRI / SNRI drug class increase in prescriptions in the 10 years available statistics.
Adjusting the median increases in SSRI / SNRIs total prescriptions 1998 to 2008 by removing year 2004 from the equation, increases the median total for 9 of the 10 years from over 1.61 Million per annum to over 1.74 Million.
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007: